Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.60 |
| ▸ | MMP9 | P14780 | 5/20 | 0.60 |
| ▸ | MMP13 | P45452 | 4/20 | 0.60 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.57 |
| ▸ | MMP1 | P03956 | 3/20 | 0.56 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | GYS1 | P13807 | 7/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26627417 | 0.89 | MMP2 (0.50) | MMP2MMP9MMP13CAPN1MMP1 | |
| SCHEMBL30603052 | 0.87 | MMP2 (0.48) | MMP2MMP9MMP13CAPN1MMP1 | |
| SCHEMBL12555619 | 0.87 | MMP2 (0.46) | MMP2MMP9MMP13CAPN1MMP1 | |
| SCHEMBL1612206 | 0.85 | MMP2 (0.56) | MMP2MMP9MMP13CAPN1MMP1 | |
| SCHEMBL1611046 | 0.84 | MMP2 (0.64) | MMP2MMP9MMP13CAPN1MMP1 | |
| SCHEMBL1764763 | 0.83 | MMP2 (0.46) | MMP2MMP9MMP13CAPN1MMP1 | |
| SCHEMBL19401473 | 0.82 | GYS1 (0.45) | MMP2MMP9MMP13CAPN1MMP1 | |
| SCHEMBL1764679 | 0.82 | GYS1 (0.45) | MMP2MMP9MMP13CAPN1MMP1 | |
| SCHEMBL12585485 | 0.82 | GYS1 (0.65) | MMP2MMP9MMP13CAPN1MMP1 | |
| SCHEMBL22996950 | 0.77 | FKBP1A (0.44) | MMP2MMP9MMP13FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023209090-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR APPLICATION IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-11-02 | — | — | WO | disclosed |
| EP-2504324-B1 | SULTAM DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-02-25 | — | — | EP | disclosed |
| US-8314250-B2 | Sultam derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314250-B2 | Sultam derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314250-B2 | Sultam derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2504324-A1 | SULTAM DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011064141-A1 | SULTAM DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-03 | — | — | WO | disclosed |
| US-20110124686-A1 | SULTAM DERIVATIVES | ANDERSON KEVIN W | 2011-05-26 | — | — | US | disclosed |
| US-20110124686-A1 | SULTAM DERIVATIVES | ANDERSON KEVIN W | 2011-05-26 | — | — | US | disclosed |
| US-20110124686-A1 | SULTAM DERIVATIVES | ANDERSON KEVIN W | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124686-A1 | SULTAM DERIVATIVES | SULT1A1, SULT2A1, SULT1E1 | MMP2 1075/4885MMP9 338/4885MMP13 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.